Advanced Solid Tumors

An exciting new combination to treat advanced solid tumors

MEDI1191 with durvalumab in advanced solid tumors

New Solid Tumors Clinical Trial: BMS-986315 for Solid Tumors, Advanced Solid Tumors

Power Life Sciences

Highlights on CAR T cells in advanced solid tumours @AACR 2022

European Society for Medical Oncology (ESMO)

B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6

TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumors

New Advanced Solid Tumors Clinical Trial: AMG 193 for Advanced MTAP-null Solid Tumors

Power Life Sciences

Dr. Adusumilli on Autologous Mesothelin-Targeted CAR T Cells in Advanced Solid Tumors

Progress in Treating Advanced Thyroid Cancers with Dr. Wirth | Targeted Therapy Insights

THANC Foundation

PATRIOT: ATR inhibitor monotherapy in advanced solid tumors

Avelumab in locally advanced or metastatic solid tumors

Phase I/II trial of dendrimer-enhanced SN38 in patients with advanced solid tumors

Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors

Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors

Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors

ST101: targeting C/EBPβ in patients with advanced solid tumors

STK-012-101: STK-012 in advanced solid tumors

Investigating the ATR inhibitor elimusertib in advanced solid tumors

TRESR trial: Novel ATR inhibitor, RP-3500, for advanced solid tumors